Therapeutic options such as GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists, SGLT2 inhibitors, and orlistat have significantly expanded the available treatments for obesity and Type 2 Diabetes. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.